Amgen vs Coca-Cola: Founders, CEOs and History

Company facts

Founders

CEOs and their tenures

Timeline: Amgen and Coca-Cola side by side

1. 1892Coca-Cola

   The Coca-Cola Company Founded

   Asa Griggs Candler incorporated The Coca-Cola Company in Atlanta in 1892 after acquiring rights connected to John Pemberton's original formula.

2. 1899Coca-Cola

   National Bottling Rights Granted

   In 1899, Benjamin F. Thomas and Joseph B. Whitehead secured rights to bottle Coca-Cola across much of the United States. The deal looked less important than the fountain business at first, but it became the foundation of Coca-Cola's physical reach.

3. 1915Coca-Cola

   Contour Bottle Introduced

   Coca-Cola introduced the contour bottle design in 1915 to make the product recognizable and harder to imitate. At a time when copycat colas were common, the bottle gave consumers a visual and tactile cue that they were buying the real product.

4. 1919Coca-Cola

   Company Sold for $25 Million

   In 1919, the Candler family sold Coca-Cola to a group of investors led by Ernest Woodruff for $25 million. The transaction signaled that Coca-Cola had become a valuable national business rather than a regional success.

5. 1928Coca-Cola

   Olympic Sponsorship Begins

   Coca-Cola began its Olympic sponsorship in 1928, linking the brand to international sport and public celebration. The partnership mattered because it gave Coca-Cola a platform that crossed language and national boundaries.

6. 1980Amgen

   Applied Molecular Genetics is incorporated

   Applied Molecular Genetics (AMGen) was incorporated on April 8, 1980 in Thousand Oaks, California, as the idea of venture capitalist William K. Bowes Jr. and a group of scientific collaborators.

7. 1983Amgen

   Nasdaq listing and the erythropoietin clone

   Amgen completed its initial public offering on June 17, 1983, raising nearly US$40 million under chief financial officer Gordon Binder, and formally shortened its name to Amgen.

8. 1984Amgen

   Kirin-Amgen joint venture formed

   Amgen and Kirin Brewery Company of Japan formed Kirin-Amgen in 1984 as a joint venture for the worldwide commercialization of erythropoietin.

9. 1985Amgen

   G-CSF cloned, leading to Neupogen

   While Fu-Kuen Lin's team worked on erythropoietin, researcher Larry Souza and his group cloned and expressed human granulocyte colony-stimulating factor in 1985.

10. 1985Coca-Cola

    New Coke Reversal

    Coca-Cola introduced New Coke in 1985 after taste tests suggested a sweeter formula could compete more effectively with Pepsi. Consumers rejected the change because the original product had emotional and cultural value beyond flavor.

11. 1989Amgen

    FDA approves Epogen

    The FDA approved Epogen (epoetin alfa) on June 1, 1989 for anemia in patients with chronic kidney failure on dialysis. It was the first commercial recombinant human erythropoietin. Epogen's U.S.

12. 1991Amgen

    Neupogen approved, giving Amgen a second franchise

    The FDA approved Neupogen (filgrastim) in February 1991. By stimulating white blood cell production it reduced the risk of infection in cancer patients with chemotherapy-induced neutropenia.

13. 1991Amgen

    Amgen wins the erythropoietin patent fight

    On March 6, 1991 the U.S. Court of Appeals for the Federal Circuit upheld the Kirin-Amgen erythropoietin patent and ruled against Genetics Institute in Amgen v. Chugai Pharmaceutical and Genetics Institute.

14. 2001Amgen

    FDA approves Aranesp, the longer-acting EPO

    Aranesp (darbepoetin alfa), an erythropoietin analogue with modified glycosylation and a longer half-life, was approved in 2001. Less frequent dosing than Epogen improved convenience and gave Amgen a newer, higher-priced product to migrate patients toward.

15. 2002Amgen

    US$16 billion Immunex acquisition brings Enbrel in-house

    Amgen completed its acquisition of Immunex Corporation on July 16, 2002, the largest biotechnology deal to that point at about US$16 billion in stock and cash.

16. 2008Coca-Cola

    Muhtar Kent Becomes CEO

    Muhtar Kent became CEO in 2008 during a period when emerging markets, bottler alignment, and category diversification were becoming more important.

17. 2009Coca-Cola

    Freestyle Fountain System Unveiled

    Coca-Cola unveiled Freestyle in 2009, giving foodservice customers a fountain dispenser with more than 100 beverage choices.

18. 2010Amgen

    Prolia and XGEVA create the bone health franchise

    The FDA approved Prolia (denosumab) for postmenopausal osteoporosis in June 2010 and XGEVA, the same molecule at a higher dose, for prevention of skeletal-related events in cancer patients in November 2010.

19. 2017Coca-Cola

    Topo Chico Joins the Portfolio

    Coca-Cola acquired Topo Chico in 2017, adding a premium sparkling mineral water brand sourced from Cerro del Topo Chico in northern Mexico.

20. 2017Coca-Cola

    James Quincey Becomes CEO

    James Quincey became CEO in 2017 and accelerated the push toward a total beverage strategy. He emphasized revenue growth management, zero-sugar products, refranchising discipline, and fewer but stronger brands.

21. 2019Amgen

    US$13.4 billion purchase of Otezla from Celgene

    Amgen agreed in August 2019 to buy worldwide rights to Otezla (apremilast) from Celgene for US$13.4 billion in cash, or about US$11.2 billion net of the present value of US$2.2 billion of anticipated future cash tax benefits, and closed on November 21, 2019.

22. 2019Coca-Cola

    Costa Coffee Acquisition

    Coca-Cola completed the Costa Coffee acquisition in 2019, adding a coffee platform with retail stores, Costa Express vending, for-home formats, and ready-to-drink potential.

23. 2020Amgen

    Amgen joins the Dow Jones Industrial Average

    Amgen replaced Pfizer in the Dow Jones Industrial Average on August 31, 2020, becoming one of the thirty components in the index. Inclusion recognized the scale Amgen had reached and added passive demand from Dow-tracking funds.

24. 2021Coca-Cola

    BodyArmor Full Acquisition

    Coca-Cola acquired full control of BodyArmor in 2021 in a transaction valued at about $5.6 billion for the remaining stake. The deal deepened Coca-Cola's position in sports drinks, a category long led by PepsiCo's Gatorade.

25. 2023Amgen

    US$27.8 billion Horizon Therapeutics acquisition closes

    Amgen completed the acquisition of Horizon Therapeutics plc on October 6, 2023 for US$116.50 per share in cash, an equity value of about US$27.8 billion, after settling FTC litigation with a behavioral consent decree.

26. 2023Coca-Cola

    $45.8B Revenue

    In FY2023, Coca-Cola reported $45.8 billion in revenue, continuing its recovery from the pandemic-era decline in away-from-home channels.

27. 2024Amgen

    Imdelltra becomes the first T-cell engager for small cell lung cancer

    The FDA granted accelerated approval to tarlatamab, sold as Imdelltra, on May 16, 2024 for extensive stage small cell lung cancer that has progressed on or after platinum-based chemotherapy.

28. 2024Coca-Cola

    $47.1B Revenue

    In FY2024, Coca-Cola reported $47.1 billion in revenue, with organic performance supported heavily by price/mix and concentrate sales timing.

29. 2025Amgen

    VESALIUS-CV extends the Repatha case to primary prevention

    In November 2025 Amgen reported Phase 3 VESALIUS-CV results in more than 12,000 patients with atherosclerosis or diabetes but no prior heart attack or stroke.

30. 2025Coca-Cola

    $47.9B Revenue and 65,900 Employees

    In FY2025, Coca-Cola reported $47.9 billion in revenue and $13.1 billion in net income. Its 2025 Form 10-K listed about 65,900 company employees at year-end, down from about 69,700 in 2024 because of divestiture activity.

31. 2026Amgen

    Medicare price setting reaches Enbrel and Otezla

    Enbrel's negotiated Medicare price under the Inflation Reduction Act took effect on January 1, 2026, after it was named in the first round of ten drugs selected for negotiation.

Acquisitions

Questions about Amgen vs Coca-Cola